Payment overview · 2025
General Payments
$1,671.65
86 reported records · 18 companies
Healthcare provider profile · identity verified
Kumar P Yogesh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DRESDEN, TN · NPI 1366430993
Verified facts
What the public records show
CMS Open Payments records show Kumar P Yogesh, M.D. received $1,671.65 in general payments during 2025 across 86 reported records.
GlaxoSmithKline, LLC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ofev, Opsumit, Ozempic, Rybelsus, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 760 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $381.59 | 22.8% | 25 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $169.67 | 10.2% | 9 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $167.63 | 10.0% | 9 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $155.92 | 9.3% | 7 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $141.77 | 8.5% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $126.87 | 7.6% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $113.04 | 6.8% | 7 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $93.19 | 5.6% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $66.50 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.46 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.00 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.00 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.67 | 1.9% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $28.14 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.98 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.25 | 1.6% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $19.58 | 1.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.39 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,637.65 | 85 |
| Education | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $280.67 | 16 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $249.40 | 19 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $169.67 | 9 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $155.92 | 7 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $141.77 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $132.19 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $126.87 | 5 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $93.19 | 5 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $66.50 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $42.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $19.58 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OFEV ofev |
2025 | Ofev | 2024 | 58 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 760 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
760 | 200 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 760 | 200 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 469 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 103 |
| Omeprazole | Omeprazole | 288 | 91 |
| Montelukast Sodium | Montelukast Sodium | 281 | 98 |
| Furosemide | Furosemide | 255 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 82 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 222 | 67 |
| Gabapentin | Gabapentin | 219 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 65 |
| Potassium Chloride | Potassium Chloride | 191 | 50 |
| Methylprednisolone | Methylprednisolone | 177 | 129 |
| Prednisone | Prednisone | 172 | 106 |
| Tramadol Hcl | Tramadol Hcl | 172 | 50 |
| Metformin Hcl | Metformin Hcl | 166 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 74 |
| Meloxicam | Meloxicam | 158 | 60 |
| Lisinopril | Lisinopril | 152 | 55 |
| Simvastatin | Simvastatin | 124 | 38 |
| Jardiance | Empagliflozin | 119 | 26 |
| Azithromycin | Azithromycin | 116 | 99 |
| Trazodone Hcl | Trazodone Hcl | 112 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 41 |
| Farxiga | Dapagliflozin Propanediol | 102 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 40 |
| Ezetimibe | Ezetimibe | 99 | 34 |
| Lorazepam | Lorazepam | 99 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 38 |
| Finasteride | Finasteride | 98 | 36 |
| Clonazepam | Clonazepam | 95 | 26 |
| Ozempic | Semaglutide | 92 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 26 |
| Cephalexin | Cephalexin | 78 | 61 |
| Losartan Potassium | Losartan Potassium | 76 | 27 |
| Glipizide | Glipizide | 74 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 15 |
| Eliquis | Apixaban | 68 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 28 |
| Carvedilol | Carvedilol | 62 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 39 |
| Famotidine | Famotidine | 58 | 15 |
| Ofev | Nintedanib Esylate | 58 | 12 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | 11 |
| Glimepiride | Glimepiride | 54 | 13 |
| Sertraline Hcl | Sertraline Hcl | 54 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 19 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 48 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 16 |
| Terazosin Hcl | Terazosin Hcl | 44 | 18 |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Dupixent Pen | Dupilumab | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Pirfenidone | Pirfenidone | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 19 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Opsumit | Macitentan | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dupixent Syringe | Dupilumab | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,671.65 · 86 records | GlaxoSmithKline, LLC. | AIRSUPRA, Arikayce, Brinsupri, DUPIXENT, FASENRA, Hillrom - Vest System Model 105 Home Care, Kerendia, NUCALA, OFEV, OPSUMIT, OPSYNVI, Ohtuvayre, Ozempic, Rybelsus, SMARTVEST, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, WAKIX, WINREVAIR, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ofev play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error